ENPEP Antibody

What is ENPEP and why is it important in research?

ENPEP (Glutamyl Aminopeptidase/Aminopeptidase A) is a membrane-bound zinc metallopeptidase that plays critical roles in multiple physiological systems. This protein is particularly important in research due to its involvement in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), where it helps control vascular tone and fluid balance. Additionally, ENPEP contributes to the metabolism of bioactive peptides, modulates immune responses by affecting T cell and macrophage activity, and participates in extracellular matrix remodeling processes.

Research interest in ENPEP has intensified following evidence of its potential role as a viral cofactor in SARS-CoV-2 pathophysiology, similar to ACE2. Its expression correlates highly with known human coronavirus receptors such as aminopeptidase N (APN) and dipeptidyl peptidase 4 (DPP4), making it relevant for infectious disease research. Dysregulation of ENPEP activity has also been implicated in various pathological conditions including hypertension, heart failure, and cancer, highlighting its significance as a research target.

What are the common applications for ENPEP antibodies in research?

ENPEP antibodies serve multiple research applications depending on their specificity and host origin. The most common applications include:

• Western Blotting (WB): Used to detect and quantify ENPEP protein expression in tissue or cell lysates, with typical recommended dilutions ranging from 1:500 to 1:2000 depending on the specific antibody.

• Immunohistochemistry (IHC): Applied to localize ENPEP protein in tissue sections, often at dilutions between 1:50 and 1:200, revealing its distribution patterns across different cell types.

• ELISA: Employed for quantitative measurement of ENPEP in solution, particularly useful for screening studies or when quantitative data is needed.

• Immunoprecipitation (IP): Used to isolate ENPEP protein from complex biological samples for downstream analysis.

• Immunocytochemistry (ICC): Applied to visualize ENPEP distribution within cultured cells.

• Flow Cytometry (FACS): Used to analyze ENPEP expression in individual cells, particularly useful for characterizing cell populations.

These applications enable researchers to study ENPEP's expression patterns, tissue localization, protein interactions, and potential roles in various physiological and pathological processes.

What types of ENPEP antibodies are available and how do they differ?

Researchers have access to several types of ENPEP antibodies that differ in their production methods, host species, and targeting characteristics:

Different host species offer varying cross-reactivity profiles. For instance, some ENPEP antibodies derived from goat serum demonstrate cross-reactivity with human, rat, cow, dog, mouse, and pig samples, making them versatile for comparative studies. Meanwhile, certain rabbit polyclonal antibodies target specific amino acid sequences such as 708-957 of human ENPEP (NP_001968.3).

The preparation methods also vary significantly - from traditional immunization approaches to recombinant technologies. Recombinant monoclonal antibodies are produced by first harvesting and sequencing the ENPEP monoclonal antibody gene, constructing a gene-carrying vector, and transfecting it into a host cell line. These antibodies typically undergo affinity chromatography purification and rigorous testing via ELISA and IHC assays to ensure specificity.

What are the optimal storage and handling conditions for ENPEP antibodies?

Proper storage and handling of ENPEP antibodies are essential for maintaining their activity and specificity. Most ENPEP antibodies should be stored according to these guidelines:

• Long-term storage: -20°C to -70°C for up to 12 months from the date of receipt in the supplied form. This temperature range minimizes degradation and preserves antibody activity.

• Medium-term storage: 2°C to 8°C under sterile conditions for up to 1 month after reconstitution. This temperature range is suitable for antibodies that are being actively used.

• Extended storage after reconstitution: -20°C to -70°C under sterile conditions for up to 6 months.

To maintain antibody integrity, it's crucial to avoid repeated freeze-thaw cycles, which can lead to denaturation and loss of binding capacity. Using a manual defrost freezer rather than an auto-defrost model helps prevent temperature fluctuations that could damage the antibody.

When working with ENPEP antibodies, aliquoting the stock solution into smaller volumes before freezing allows researchers to thaw only what is needed for immediate use, thereby preserving the remaining stock. Additionally, maintaining sterile conditions during handling prevents contamination that could interfere with experimental results or cause degradation of the antibody.

How should researchers validate ENPEP antibody specificity for their experimental systems?

Validating ENPEP antibody specificity is critical for ensuring reliable research outcomes. A comprehensive validation strategy should include multiple complementary approaches:

• Positive and negative control samples: For ENPEP antibodies, mouse lung tissue has been identified as a positive control sample that reliably expresses the target protein. Researchers should include tissues or cell lines known to express high levels of ENPEP (small intestine enterocytes, kidney cortex) as positive controls and those with minimal expression as negative controls.

• Knockdown/knockout validation: Generating ENPEP knockdown or knockout samples provides one of the most rigorous specificity tests. Compare antibody reactivity between wild-type cells and those with ENPEP expression reduced or eliminated through siRNA, CRISPR-Cas9, or other genetic approaches.

• Peptide competition assays: Pre-incubate the ENPEP antibody with the immunizing peptide (e.g., the EQYQKTSLAQEKEK sequence for certain internal region-targeting antibodies) before application in your experimental system. Signal elimination or significant reduction confirms specificity for the target epitope.

• Multiple antibody comparison: Employ several ENPEP antibodies that target different epitopes (e.g., comparing an antibody targeting AA 708-957 with one targeting AA 899-930). Concordant detection patterns across these antibodies strengthen confidence in specificity.

• Cross-platform validation: Confirm ENPEP detection across multiple techniques (e.g., WB, IHC, and mass spectrometry). For instance, if an ENPEP band is detected at the expected molecular weight via Western blot, verify this finding with immunoprecipitation followed by mass spectrometry.

• Recombinant protein controls: Use purified recombinant ENPEP protein as a defined standard to confirm antibody binding characteristics and establish detection limits for quantitative applications.

Thorough validation is especially important when studying ENPEP in novel contexts or unexplored tissues, as its expression is highly tissue-specific and subject to age-related variations.

What are the key considerations for optimizing ENPEP antibody use in immunohistochemistry?

Optimizing ENPEP antibody use in immunohistochemistry (IHC) requires careful attention to several technical factors:

• Tissue-specific fixation protocols: ENPEP, as a membrane-bound protein, requires particular attention to fixation methods. Overfixation can mask epitopes, while inadequate fixation may compromise tissue morphology. For studying ENPEP in vascular tissues, shorter fixation times (4-8 hours) with 4% paraformaldehyde are often optimal, whereas kidney tissue may require specialized fixatives that preserve both membrane integrity and antigenicity.

• Antigen retrieval optimization: ENPEP epitopes often require heat-induced epitope retrieval (HIER) for optimal detection. Compare multiple buffer systems (citrate pH 6.0, EDTA pH 8.0, Tris-EDTA pH 9.0) to determine which best unmasks ENPEP epitopes in your specific tissue. For tissues with high ENPEP expression in pericytes, such as brain vasculature, EDTA-based retrieval often yields superior results.

• Antibody dilution titration: While manufacturer recommendations provide starting points (e.g., 1:50-1:200 for many ENPEP antibodies), systematic titration is essential. Prepare a dilution series and assess signal-to-noise ratio across tissues with varying ENPEP expression levels.

• Detection system selection: For tissues with low ENPEP expression (such as lung epithelium), amplification systems such as tyramide signal amplification may be necessary. Conversely, tissues with abundant expression (small intestine, kidney) may yield cleaner results with direct detection methods.

• Counterstain optimization: When studying ENPEP in highly vascularized tissues, dual immunofluorescence with endothelial markers (CD31) and pericyte markers (PDGFRβ) can help distinguish ENPEP-positive pericytes from other vascular cells. This approach is particularly valuable in brain and heart tissues where ENPEP expression has been documented in vascular smooth muscle cells.

• Incubation conditions: ENPEP antibody binding may be temperature-dependent. Compare overnight incubation at 4°C versus shorter incubations at room temperature to determine optimal conditions for your specific antibody and tissue combination.

• Negative controls: Include isotype controls matched to your ENPEP antibody's host species and immunoglobulin subclass to distinguish true staining from non-specific binding or endogenous peroxidase activity.

How do age and sex influence ENPEP expression, and how should this impact experimental design?

Age and sex significantly influence ENPEP expression patterns across tissues, requiring careful consideration in experimental design:

• Age-dependent expression changes: Bioinformatic analyses of RNA-Seq datasets reveal that ENPEP expression increases with age in skeletal muscle and prostate tissue, while decreasing in heart and aorta. These age-dependent changes necessitate age-matched controls in studies involving these tissues. When investigating vascular pathologies using ENPEP as a marker, researchers should account for the confounding effect of age-related expression decline in cardiovascular tissues.

• Sex-specific expression patterns: While less extensively documented than age effects, sex-based differences in ENPEP expression should be considered, particularly in tissues subject to hormonal regulation. When designing experiments investigating ENPEP in prostate tissue, where expression increases with age, both age and hormonal status should be controlled variables.

• Tissue-specific considerations: The effect of age on ENPEP expression varies dramatically by tissue type. In experimental designs involving multiple tissue comparisons, researchers should be aware that age-normalization may need to be tissue-specific. For instance, using young animals for heart studies but older animals for skeletal muscle studies could lead to more consistent ENPEP detection.

• Statistical power calculations: When planning studies examining ENPEP expression in age-variable tissues, increased biological replication may be necessary to account for age-related variability. Power analyses should incorporate the known variance introduced by age factors.

• Control selection strategy: Rather than simple age-matching, researchers may need to stratify controls across age ranges to capture the dynamic nature of ENPEP expression over the lifespan. This is particularly important for longitudinal studies or those comparing disease models across different age groups.

• Developmental timing considerations: Studies involving ENPEP during development should recognize that its expression in certain tissues follows specific developmental programs. Careful staging and timing of experimental interventions are essential for reproducible results.

By accounting for these age and sex influences, researchers can design more rigorous experiments that minimize confounding variables and enhance reproducibility when studying ENPEP across different physiological and pathological contexts.

What are the technical challenges in detecting ENPEP in single-cell analyses and how can they be overcome?

Single-cell analysis of ENPEP presents several technical challenges due to its tissue-specific expression patterns and varying abundance levels:

• Low expression in certain cell types: ENPEP is expressed at low levels in lower respiratory epithelium but shows higher expression in para-alveolar fibroblasts in the lung. This variability creates detection challenges in single-cell RNA-seq experiments where capture efficiency and sequencing depth may limit detection of lowly expressed genes. To overcome this limitation:

  • Implement targeted sequencing approaches for ENPEP and related genes to increase read depth

  • Use computational imputation methods specifically designed for low-abundance transcripts

  • Consider cell enrichment strategies before sequencing to concentrate ENPEP-expressing populations

• Cell type heterogeneity: ENPEP is widely expressed in specific subsets of vascular smooth muscle cells (likely pericytes) across systemic vasculature, heart, and brain, while also appearing in a substantial fraction of ependymal cells. This heterogeneous expression pattern presents challenges for single-cell protein detection. Solutions include:

  • Implementing multi-parameter flow cytometry with carefully selected marker panels to distinguish ENPEP-expressing cell populations

  • Using index sorting approaches that preserve information about cellular location or morphology alongside ENPEP expression data

  • Employing spatial transcriptomics methods to maintain tissue context while assessing single-cell expression

• Epitope accessibility in membrane proteins: As a membrane-bound zinc metallopeptidase, ENPEP's structural characteristics can complicate antibody-based detection in single-cell protein assays. To address this:

  • Optimize cell fixation and permeabilization protocols specifically for membrane proteins

  • Test multiple antibody clones targeting different ENPEP epitopes to identify those with superior performance in single-cell applications

  • Consider native protein detection methods that preserve membrane protein conformation

• Reference gene selection for normalization: Traditional housekeeping genes may not maintain stable expression across all ENPEP-expressing cell types. Researchers should:

  • Validate reference genes specifically in ENPEP-expressing cell populations

  • Consider computational normalization approaches that don't rely on pre-selected reference genes

  • Implement spike-in controls for more reliable normalization

• Data analysis considerations: The bimodal expression pattern of ENPEP (high expression in specific cell types, minimal in others) requires specialized analytical approaches:

  • Apply zero-inflated statistical models appropriate for sparse single-cell data

  • Implement clustering algorithms that can identify rare cell populations where ENPEP may be highly expressed

  • Use trajectory analysis methods to capture dynamic changes in ENPEP expression during cellular differentiation or response to stimuli

Through careful optimization of these technical aspects, researchers can effectively study ENPEP at single-cell resolution, revealing its cell type-specific functions and regulatory patterns.

How can ENPEP antibodies be leveraged to investigate its role in the renin-angiotensin-aldosterone system and pathological conditions?

ENPEP antibodies provide powerful tools for investigating this protein's role in the renin-angiotensin-aldosterone system (RAAS) and related pathological conditions:

• Functional blocking studies: ENPEP plays a critical role in the RAAS by controlling angiotensin metabolism. Blocking antibodies can be used to selectively inhibit ENPEP's enzymatic activity in experimental systems to evaluate its specific contributions to:

  • Angiotensin II to angiotensin III conversion kinetics in tissue-specific contexts

  • Blood pressure regulation mechanisms in ex vivo vessel preparations

  • Pathological RAAS activation in models of hypertension and heart failure

• Co-localization with RAAS components: Multiplexed immunofluorescence combining ENPEP antibodies with antibodies against other RAAS components (ACE, ACE2, AT1R) can reveal:

  • Spatial relationships between ENPEP and other RAAS proteins in tissue microenvironments

  • Cell-specific co-expression patterns in vascular smooth muscle cells versus endothelial cells

  • Changes in relative localization under pathological conditions like hypertension

• Quantitative expression analysis in disease models: Western blotting and quantitative IHC using validated ENPEP antibodies allow researchers to:

  • Track ENPEP expression changes during disease progression in models of hypertension, heart failure, and kidney disease

  • Correlate ENPEP levels with physiological parameters and disease severity

  • Assess the impact of therapeutic interventions on ENPEP expression

• Protein-protein interaction studies: Using ENPEP antibodies for co-immunoprecipitation experiments enables investigation of:

  • Direct interactions between ENPEP and other RAAS components

  • Novel binding partners in different tissue environments

  • Protein complex formation under normal versus pathological conditions

• In vivo tracking of ENPEP-expressing cells: Fluorescently labeled ENPEP antibodies can be used for intravital microscopy to:

  • Track dynamic changes in ENPEP-expressing cells during disease progression

  • Monitor pericyte behavior in real-time in models of vascular dysfunction

  • Evaluate cellular responses to pharmacological RAAS modulators

• Therapeutic target validation: ENPEP antibodies can help validate this protein as a potential therapeutic target by:

  • Establishing tissue distribution patterns to predict on-target and off-target effects

  • Confirming ENPEP upregulation in disease-relevant tissues

  • Demonstrating efficacy of ENPEP-targeting approaches in preclinical models

These approaches leverage ENPEP antibodies beyond basic expression analysis to gain functional insights into ENPEP's role in health and disease, particularly within the RAAS regulatory network.

What are the best practices for using ENPEP antibodies in comparative studies across species?

When conducting comparative studies of ENPEP across species, researchers should address several methodological considerations:

By addressing these considerations, researchers can conduct more reliable comparative studies of ENPEP across species, gaining insights into evolutionary conservation and species-specific functions of this important enzyme.

How can researchers troubleshoot common issues with ENPEP antibodies in experimental applications?

When encountering challenges with ENPEP antibodies, systematic troubleshooting approaches can help resolve common issues:

• Weak or absent signal in Western blotting:

  • Confirm sample preparation: ENPEP is a membrane-bound protein requiring appropriate lysis conditions. Use detergent-based buffers (RIPA or NP-40) with brief sonication to effectively solubilize membrane proteins.

  • Optimize protein loading: For tissues with lower ENPEP expression (such as lung epithelium), increase protein loading to 50-75 μg per lane.

  • Adjust transfer conditions: ENPEP's large size (approximately 160 kDa) may require extended transfer times or lower voltage settings to ensure complete transfer to the membrane.

  • Try alternative reducing conditions: Some ENPEP epitopes may be sensitive to harsh reducing agents; test milder reduction conditions.

• High background in immunohistochemistry:

  • Implement additional blocking steps: For tissues with high endogenous biotin (such as kidney), use avidin/biotin blocking steps before primary antibody incubation.

  • Optimize antibody concentration: Excessive antibody can cause high background; test multiple dilutions beyond the recommended range (e.g., 1:300-1:500 instead of 1:50-1:200).

  • Consider alternative detection systems: Switch from ABC-based to polymer-based detection systems that may offer cleaner results for ENPEP detection.

  • Use tissue-specific blocking agents: For tissues with high endogenous immunoglobulin content, include species-specific F(ab) fragments in blocking solutions.

• Inconsistent or unexpected molecular weight:

  • Account for glycosylation: ENPEP is heavily glycosylated, which can affect apparent molecular weight. Treatment with glycosidases can confirm specificity.

  • Check for proteolytic processing: ENPEP may undergo tissue-specific processing; compare reducing and non-reducing conditions to identify potential dimers or processed forms.

  • Verify with multiple antibodies: Use antibodies targeting different ENPEP epitopes to confirm unusual banding patterns.

• Poor reproducibility between experiments:

  • Standardize sample collection: ENPEP expression may be sensitive to experimental conditions; ensure consistent timing and processing of samples.

  • Control for age and sex variables: Given known effects of age on ENPEP expression in certain tissues, tight control of these variables is essential.

  • Implement quantitative controls: Include standard curves with recombinant ENPEP protein in quantitative applications.

• Cross-reactivity concerns:

  • Verify with knockout/knockdown controls: Test antibody specificity in systems with confirmed ENPEP depletion.

  • Peptide competition: Pre-absorb antibody with immunizing peptide to confirm specificity of detected signals.

  • Mass spectrometry validation: For critical experiments, confirm antibody targets by immunoprecipitation followed by mass spectrometry.

• Tissue-specific detection challenges:

  • Optimize fixation for specific tissues: ENPEP detection in vascular tissues may require different fixation than in epithelial tissues.

  • Adjust antigen retrieval: Different tissues may require distinct antigen retrieval methods to unmask ENPEP epitopes effectively.

  • Consider alternative antibody clones: If one antibody performs poorly in a specific tissue, test alternatives targeting different epitopes.

Through systematic troubleshooting focusing on these common issues, researchers can optimize ENPEP antibody performance across experimental applications.